Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Theranostics 2015; 5(12):1388-1401. doi:10.7150/thno.13348 This issue Cite

Review

PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status

Susanne Lütje1, 2,✉, Sandra Heskamp2, Alexander S. Cornelissen2, Thorsten D. Poeppel1, Sebastiaan A. M. W. van den Broek3, Sandra Rosenbaum-Krumme1, Andreas Bockisch1, Martin Gotthardt2, Mark Rijpkema2, Otto C. Boerman2

1. Department of Nuclear Medicine, University Medical Center Essen, University Duisburg-Essen, Germany
2. Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
3. FutureChemistry Holding BV, Nijmegen, The Netherlands

✉ Corresponding author: Susanne Lütje, MD, PhD, University Medical Center Essen, Department of Nuclear Medicine, Hufelandstraße 55, 45122 Essen, Germany. Phone: +49 201 - 723 83663; Email: Susanne.Luetjede

Citation:
Lütje S, Heskamp S, Cornelissen AS, Poeppel TD, Broek SAMWvd, Rosenbaum-Krumme S, Bockisch A, Gotthardt M, Rijpkema M, Boerman OC. PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status. Theranostics 2015; 5(12):1388-1401. doi:10.7150/thno.13348. https://www.thno.org/v05p1388.htm
Other styles

File import instruction

Abstract

Graphic abstract

Prostate cancer (PCa) is the most common malignancy in men worldwide, leading to substantial morbidity and mortality. At present, imaging of PCa has become increasingly important for staging, restaging, and treatment selection. Until recently, choline-based positron emission tomography/computed tomography (PET/CT) represented the state-of-the-art radionuclide imaging technique for these purposes. However, its application is limited to patients with high PSA levels and Gleason scores. Prostate-specific membrane antigen (PSMA) is a promising new target for specific imaging of PCa, because it is upregulated in the majority of PCa. Moreover, PSMA can serve as a target for therapeutic applications. Currently, several small-molecule PSMA ligands with excellent in vivo tumor targeting characteristics are being investigated for their potential in theranostic applications in PCa. Here, a review of the recent developments in PSMA-based diagnostic imaging and therapy in patients with PCa with radiolabeled PSMA ligands is provided.

Keywords: PSMA, prostate cancer, PET, radionuclide imaging, theranostics

Citation styles

APA
Lütje, S., Heskamp, S., Cornelissen, A.S., Poeppel, T.D., Broek, S.A.M.W.v.d., Rosenbaum-Krumme, S., Bockisch, A., Gotthardt, M., Rijpkema, M., Boerman, O.C. (2015). PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status. Theranostics, 5(12), 1388-1401. https://doi.org/10.7150/thno.13348.

ACS
Lütje, S.; Heskamp, S.; Cornelissen, A.S.; Poeppel, T.D.; Broek, S.A.M.W.v.d.; Rosenbaum-Krumme, S.; Bockisch, A.; Gotthardt, M.; Rijpkema, M.; Boerman, O.C. PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status. Theranostics 2015, 5 (12), 1388-1401. DOI: 10.7150/thno.13348.

NLM
Lütje S, Heskamp S, Cornelissen AS, Poeppel TD, Broek SAMWvd, Rosenbaum-Krumme S, Bockisch A, Gotthardt M, Rijpkema M, Boerman OC. PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status. Theranostics 2015; 5(12):1388-1401. doi:10.7150/thno.13348. https://www.thno.org/v05p1388.htm

CSE
Lütje S, Heskamp S, Cornelissen AS, Poeppel TD, Broek SAMWvd, Rosenbaum-Krumme S, Bockisch A, Gotthardt M, Rijpkema M, Boerman OC. 2015. PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status. Theranostics. 5(12):1388-1401.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use